X4 Pharmaceuticals (Nasdaq: XFOR) has secured US approval for Xolremdi (mavorixafor), for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).
The CXCR4 antagonist is designed to increase the number of circulating mature neutrophils and lymphocytes, and is the first therapy specifically approved for the condition.
WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by dysfunction of the CXCR4 pathway.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze